Overview

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether mild liver impairment affects blood levels of istradefylline in humans. Decreased liver function could possibly increase istradefylline levels.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Pharma, Inc.
Treatments:
Istradefylline